Piper Sandler Increases Target Price for Travere Therapeutics (TVTX)

NodeGuardian · 2026-03-10T13:32:36+00:00

Piper Sandler raised Travere Therapeutics' price target from $35 to $38 with a Neutral rating, reflecting a nearly 40% upside after strong Q4 earnings of $126.6 million in net sales and $2.7 million net income, boosted by FILSPARI.

NodeGuardian

2026-03-10 13:32:36

Abstract generation in progress

Piper Sandler has increased its price target for Travere Therapeutics (TVTX) from $35 to $38, maintaining a Neutral rating, leading to an adjusted upside potential of almost 40%. This adjustment follows the company’s strong fourth-quarter earnings, where it reported $126.6 million in U.S. net product sales and a net income of $2.7 million for the quarter, largely driven by FILSPARI sales growth. Travere Therapeutics focuses on developing therapies for rare kidney and metabolic diseases.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes